PubMed@xiajingbo:001 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PubMed@xiajingbo/sourceid/001","sourcedb":"PubMed@xiajingbo","sourceid":"001","text":"Expression of TMPRSS 2 , 4 , 11 A , 11D , and 11E on 293 / hACE2 cells enhanced SARS - CoV-2 S protein - mediated cell - cell fusion similarly to SASR - CoV S ( Supplementary Fig . 2 )\r\n\r\nACE2 expression is reduced in patients with DM possibly due to glycosylation ; this might explain the increased predisposition to severe lung injury and ARDS with COVID-19 .\r\n\r\nSimilarly , animal models have had inconsistent findings with respect to the effects of ARBs on ACE2 , with some showing that ARBs may increase messenger RNA expression or protein levels of ACE2 in tissue and others showing no effect .\r\n\r\nCompared to mock control , SARS - CoV-2 S pseudovirions showed an over 500-fold increase in luciferase activities in Calu3 cells , at a level similar to SARS - CoV S pseudovirions ( Fig . 2a )","tracks":[{"project":"AGAC-COVID-19","denotations":[{"id":"T1","span":{"begin":71,"end":79},"obj":"PosReg"},{"id":"T10","span":{"begin":696,"end":706},"obj":"Enzyme"},{"id":"T11","span":{"begin":684,"end":692},"obj":"PosReg"},{"id":"T2","span":{"begin":121,"end":132},"obj":"CPA"},{"id":"T3","span":{"begin":251,"end":264},"obj":"MPA"},{"id":"T4","span":{"begin":188,"end":192},"obj":"Gene"},{"id":"T5","span":{"begin":207,"end":214},"obj":"NegReg"},{"id":"T6","span":{"begin":461,"end":465},"obj":"Gene"},{"id":"T7","span":{"begin":509,"end":533},"obj":"MPA"},{"id":"T8","span":{"begin":555,"end":559},"obj":"Gene"},{"id":"T9","span":{"begin":500,"end":508},"obj":"PosReg"},{"id":"T12","span":{"begin":193,"end":203},"obj":"MPA"},{"id":"T13","span":{"begin":707,"end":717},"obj":"MPA"},{"id":"T14","span":{"begin":537,"end":551},"obj":"MPA"}],"attributes":[{"subj":"T1","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T10","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T11","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T2","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T3","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T4","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T5","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T6","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T7","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T8","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T9","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T12","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T13","pred":"source","obj":"AGAC-COVID-19"},{"subj":"T14","pred":"source","obj":"AGAC-COVID-19"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"AGAC-COVID-19","color":"#ec93a7","default":true}]}]}}